Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cost and dosing issues.

D Nathwani1

  • 1Infection and Immunodeficiency Unit, King's Cross Hospital, NHS Trust, Dundee, UK.

Journal of Chemotherapy (Florence, Italy)
|June 21, 2001
PubMed
Summary
This summary is machine-generated.

Ciprofloxacin is the gold-standard quinolone for many infections, though newer agents offer different dosing. Overall treatment costs, including potential

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of COVID-19 on a Major Trauma Network. An analysis of mechanism of injury pattern, referral load and operative case-mix.

Injury·2021
Same author

Predictors of extended length of stay after unicompartmental knee arthroplasty.

Journal of clinical orthopaedics and trauma·2020
Same author

Microbiological and functional outcomes after open extremity fractures sustained overseas: The experience of a UK level I trauma centre.

JPRAS open·2020
Same author

Achieving discharge within 24 h of robotic unicompartmental knee arthroplasty may be possible with appropriate patient selection and a multi-disciplinary team approach.

Journal of orthopaedics·2020
Same author

Should we routinely perform a post-operative hemoglobin check following unicompartmental knee arthroplasty?

The Knee·2020
Same author

Implementation of antibiotic stewardship in different settings - results of an international survey.

Antimicrobial resistance and infection control·2019

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Health Economics

Background:

  • Ciprofloxacin is the established standard for many infections, with twice-daily dosing.
  • Newer fluoroquinolones like trovafloxacin and grepafloxacin offer once-daily dosing options.
  • Levofloxacin may require twice-daily dosing for severe infections.

Purpose of the Study:

  • To compare the dosing, cost-effectiveness, and clinical utility of ciprofloxacin versus newer fluoroquinolone agents.
  • To explore the concept of 'cost shifting' when restricting antibiotic prescriptions.

Main Methods:

  • Comparative analysis of antibiotic dosing regimens.
  • Review of acquisition costs versus potential overall treatment costs.
  • Discussion of clinical applications and emerging trends in fluoroquinolone use.

Related Experiment Videos

Main Results:

  • Ciprofloxacin, while having a higher acquisition cost, remains the gold standard for many infections, including Pseudomonas aeruginosa.
  • Newer agents offer simplified dosing (once-daily), but their total treatment costs are not yet fully defined.
  • Cost shifting may occur, where restricting one antibiotic leads to increased use of equally or more expensive alternatives.

Conclusions:

  • The overall cost-effectiveness of newer fluoroquinolones requires further research.
  • Ciprofloxacin's broad utility, IV/oral formulations, and established efficacy solidify its role in hospital settings.
  • Newer quinolones are likely to be initially adopted for severe community-acquired pneumonia.